Myelitis associated with COVID-19: clinical, radiological, and laboratory characteristics

Abstract

Aim: The current study aimed to describe various types of myelitis associated with a novel coronavirus infection [coronavirus disease 2019 (COVID-19)] as well as to analyze cytokine profiles and cerebrospinal fluid (CSF) parameters in affected patients and to compare them to patients with other immune-mediated disorders-multiple sclerosis (MS), in order to identify possible common pathogenetic pathways and consequently treatment targets.

Methods: Clinical, radiological, and laboratory characteristics were studied based on patients’ history. CSF from patients with myelitis associated with COVID-19 (11 patients) was compared with CSF of healthy controls (HC) (7 patients) and patients with MS (37 patients) from the non-COVID era. CSF cytological examination, protein levels and oligoclonal bands (OCBs) evaluation, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus detection and cytokine profiling using Bio-Plex Pro Human Inflammation Panel 1, 37-Plex were performed.

Results: In total 11 patients with different types of myelitis developed up to 3 months after COVID-19 were enrolled in the study. Radiological findings were diverse: short transverse myelitis (lesion of fewer than 3 segments) ( n = 6), longitudinal extensive transverse myelitis (LETM) ( n = 2), multifocal spinal cord lesions ( n = 1), and myelitis involving dorsal and lateral columns ( n = 2). The most pronounced response to treatment was observed in patients with partial transverse myelitis and patients with anti-myelin oligodendrocyte glycoprotein (MOG) antibodies (MOG Abs). Multiple comparisons have demonstrated decreased levels of interleukin-10 (IL-10), interferon-α2 (IFN-α2), IFN-β, and thymic stromal lymphopoietin (TSLP), and increased IL-19 and B cell activating factor (BAFF) in patients with COVID-19 myelitis (CM) compared to the MS group. The highest BAFF and a proliferation-inducing ligand (APRIL) concentrations were found in patients with the most profound neurological disability.

Conclusions: Myelitis associated with COVID-19 is clinically and radiologically heterogeneous. Evaluation of cytokine profiles in patients with myelitis associated with COVID-19 revealed their relative similarity with ones of MS patients, except for a few cytokines. BAFF/APRIL system as well as IL-10 is well-known for the role in the development and progression of autoimmune diseases, however, their links with COVID-19 and effects on the development of immune-mediated central nervous system (CNS) disorders after SARS-CoV-2 remain to be further studied.

Keywords

Novel coronavirus infection / cytokine profile / myelitis / immune-mediated diseases / multiple sclerosis

References

[1] Paules CI, Marston HD, Fauci AS. Coronavirus infections-more than just the common cold. JAMA. 2020; 323: 707-8.

[2] Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5: 819-24.

[3] Zoghi G, Moosavy SH, Yavarian S, HasaniAzad M, Khorrami F, Sharegi Brojeni M, et al. Gastrointestinal implications in COVID-19. BMC Infect Dis. 2021; 21: 1135.

[4] Gómez-Mesa JE, Galindo-Coral S, Montes MC, Muñoz Martin AJ. Thrombosis and coagulopathy in COVID-19. Curr Probl Cardiol. 2021; 46: 100742.

[5] Guerrero JI, Barragán LA, Martínez JD, Montoya JP, Peña A, Sobrino FE, et al. Central and peripheral nervous system involvement by COVID-19: a systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings. BMC Infect Dis. 2021; 21: 515.

[6] Chou SH, Beghi E, Helbok R, Moro E, Sampson J, Altamirano V, et al. ; GCS-NeuroCOVID Consortium and ENERGY Consortium. Global incidence of neurological manifestations among patients hospitalized with COVID-19-a report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium. JAMA Netw Open. 2021; 4: e2112131.

[7] Ariño H, Heartshorne R, Michael BD, Nicholson TR, Vincent A, Pollak TA, et al. Neuroimmune disorders in COVID-19. J Neurol. 2022; 269: 2827-39.

[8] Garg RK, Paliwal VK, Gupta A. Spinal cord involvement in COVID-19: a review. J Spinal Cord Med. 2023; 46: 390-404.

[9] Espíndola OM, Gomes YCP, Brandão CO, Torres RC, Siqueira M, Soares CN, et al. Inflammatory cytokine patterns associated with neurological diseases in coronavirus disease 2019. Ann Neurol. 2021; 89: 1041-5.

[10] Jarius S, Pache F, Körtvelyessy P, Jelčić I, Stettner M, Franciotta D, et al. in cooperation with the German Society for Cerebrospinal Fluid Diagnostics and Clinical Neurochemistry. Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. J Neuroinflammation. 2022; 19: 19.

[11] Garcia MA, Barreras PV, Lewis A, Pinilla G, Sokoll LJ, Kickler T, et al. Cerebrospinal fluid in COVID-19 neurological complications: no cytokine storm or neuroinflammation. medRxiv [Preprint]. 2021: 2021.01.10.20249014.

[12] Bernard-Valnet R, Perriot S, Canales M, Pizzarotti B, Caranzano L, Castro-Jiménez M, et al. Encephalopathies associated with severe COVID-19 present neurovascular unit alterations without evidence for strong neuroinflammation. Neurol Neuroimmunol Neuroinflamm. 2021; 8: e1029.

[13] Greenberg BM, Krishnan C, Harder L. New onset transverse myelitis diagnostic accuracy and patient experiences. Mult Scler Relat Disord. 2019; 30: 42-4.

[14] West TW, Hess C, Cree BA. Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies. Semin Neurol. 2012; 32: 97-113.

[15] Huang HY, Shah LM, McNally JS, Sant T, Hutchins TA, Goldstein ED, et al. COVID-19-associated myelitis involving the dorsal and lateral white matter tracts: a case series and review of the literature. AJNR Am J Neuroradiol. 2021; 42: 1912-7.

[16] Román GC, Gracia F, Torres A, Palacios A, Gracia K, Harris D. Acute transverse myelitis (ATM): clinical review of 43 patients with COVID-19-associated ATM and 3 post-vaccination ATM serious adverse events with the ChAdOx1 nCoV-19 vaccine (AZD1222). Front Immunol. 2021; 12: 653786.

[17] Royston M, Kielhorn A, Weycker D, Shaff M, Houde L, Tanvir I, et al. Neuromyelitis optica spectrum disorder: clinical burden and cost of relapses and disease-related care in US clinical practice. Neurol Ther. 2021; 10: 767-83.

[18] Epstein SE, Levin S, Onomichi K, Langston C, Yeshokumar A, Fabian M, et al. Myelin oligodendrocyte glycoprotein (MOG) antibody-mediated disease: the difficulty of predicting relapses. Mult Scler Relat Disord. 2021; 56: 103229.

[19] Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002; 59: 499-505.

[20] Bourre B, Zéphir H, Ongagna JC, Cordonnier C, Collongues N, Debette S, et al. Long-term follow-up of acute partial transverse myelitis. Arch Neurol. 2012; 69: 357-62.

[21] Ozenci V, Kouwenhoven M, Huang YM, Xiao B, Kivisäkk P, Fredrikson S, et al. Multiple sclerosis: levels of interleukin-10-secreting blood mononuclear cells are low in untreated patients but augmented during interferon-beta-1b treatment. Scand J Immunol. 1999; 49: 554-61.

[22] Melamud MM, Ermakov EA, Boiko AS, Kamaeva DA, Sizikov AE, Ivanova SA, et al. Multiplex analysis of serum cytokine profiles in systemic lupus erythematosus and multiple sclerosis. Int J Mol Sci. 2022; 23: 13829.

[23] Marastoni D, Magliozzi R, Bolzan A, Pisani AI, Rossi S, Crescenzo F, et al. CSF levels of CXCL12 and osteopontin as early markers of primary progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021; 8: e1083.

[24] Padberg F, Feneberg W, Schmidt S, Schwarz MJ, Körschenhausen D, Greenberg BD, et al. CSF and serum levels of soluble interleukin-6 receptors (sIL-6R and sgp130), but not of interleukin-6 are altered in multiple sclerosis. J Neuroimmunol. 1999; 99: 218-23.

[25] Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. 2013; 24: 203-15.

[26] Moisini I, Davidson A. BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol. 2009; 158: 155-63.

[27] Wang H, Wang K, Zhong X, Qiu W, Dai Y, Wu A, et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol. 2012; 32: 1007-11.

[28] Alturaiki W, Alkadi H, Alamri S, Awadalla ME, Alfaez A, Mubarak A, et al. Association between the expression of toll-like receptors, cytokines, and homeostatic chemokines in SARS-CoV-2 infection and COVID-19 severity. Heliyon. 2023; 9: e12653.

[29] Cua DJ, Hutchins B, LaFace DM, Stohlman SA, Coffman RL. Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J Immunol. 2001; 166: 602-8.

[30] Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012; 32: 23-63.

[31] Gibson AW, Edberg JC, Wu J, Kimberly RP. The role of IL-10 in autoimmune pathology. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000-2013. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6234/

[32] Wei Y, Chang H, Feng H, Li X, Zhang X, Yin L. Low serum interleukin-10 is an independent predictive factor for the risk of second event in clinically isolated syndromes. Front Neurol. 2019; 10: 604.